H.P. Acthar® (repository corticotropin injection)

**BENEFIT APPLICATION**

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

**DESCRIPTION**

The intent of the H.P. Acthar® drug policy is to provide coverage for specific, but not all FDA labeled or compendial supported drug use based on plan design and the scope of the pharmacy benefit. This program provides coverage for H.P. Acthar Gel for the treatment of infantile spasms and exacerbations of multiple sclerosis if all of the approval criteria are met.

A. **Infantile spasms**: as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age
B. **Multiple Sclerosis**: treatment of acute exacerbations of multiple sclerosis in adults

The use of H.P. Acthar for the treatment of all other indications listed in the FDA product labeling has not been proven to be superior to conventional therapies (e.g., corticosteroids, immunosuppressive agents) and has a significantly higher cost than the standard of care agents. Use of H. P. Acthar for these conditions is considered not medically necessary.

A. **Rheumatic Disorders**: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis, ankylosing spondylitis
B. **Collagen Diseases**: during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)
C. **Dermatologic Diseases**: severe erythema multiforme, Stevens-Johnson syndrome
D. **Allergic States**: serum sickness
E. **Ophthalmic Diseases**: severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation
F. **Respiratory Diseases**: symptomatic sarcoidosis
G. **Edematous State**: to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus

**POLICY**

**Required Documentation**
Submission of the following information is necessary to initiate the prior authorization review for requests for treatment of multiple sclerosis exacerbations: chart notes detailing the outcomes of the most recent trial with IV methylprednisolone, including dosage and duration of treatment.
Initial Criteria For Approval

1. **Infantile Spasms**
   Authorization of 4 weeks may be granted to members who are less than 2 years of age for the treatment of infantile spasms.

2. **Multiple Sclerosis**
   Authorization of 3 weeks may be granted to members for the treatment of acute exacerbations of multiple sclerosis when the member has had an inadequate response to a trial of IV methylprednisolone (for the current exacerbation).

Continuation of Therapy

1. **Infantile Spasms**
   Authorization of 4 weeks may be granted to members requesting H.P. Acthar Gel for continuation of therapy when the member has shown substantial clinical benefit from therapy.

2. **Multiple Sclerosis**
   Authorization of 3 weeks may be granted for members requesting re-authorization for H.P. Acthar therapy when ALL initial authorization criteria are met.

_all other indications are considered not medically necessary._

**PROCEDURES AND BILLING CODES**

To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or ICD diagnostic codes.

- J0800, repository corticotropin, 40 units.

**REFERENCES**

POLICY HISTORY

Policy #: 05.01.22
Original Effective Date: January 2009
Reviewed: January 2017
Revised: May 2017
Current Effective Date: June 15, 2017